| Name | Title | Contact Details |
|---|
NextHealth Technologies (NHT), based in Denver CO, drives measurable medical cost reduction through a prescriptive analytics and consumer engagement platform. NextHealth’s proprietary SaaS platform integrates three foundational technologies - prescriptive analytics, behavioral economics, and multichannel consumer engagement. This end-to end, technology-enabled solution predicts risk reduction opportunities and then prescribes personalized member level actions or “nudges" to dramatically improve outcomes. NHT has been able to deliver a sustained and ground breaking 25% reduction in ER visits and over $17 per member per year in medical claims cost reduction for targeted commercial, ASO, and Medicaid populations. NHT offers over 30+ use cases including ER visit reduction, out-of-network reduction, and retention of high value individual members. NextHealth offers an at risk managed services contract based on 20% of causal claims savings. These results have led the company to be named by Gartner as one of the most innovative healthcare analytics vendors in the US. NHT’s multi-year software and managed services solution is currently contracted and supporting over 1.5 million members with some of the most reputable health plans in the country including: UnitedHealthcare, BlueCross BlueShield of Tennessee, and Colorado Access.
Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on transforming the treatment of vascular disease and improving patient care by combining the latest medical device
alicare is a West Harrison, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Universal Hospital Services, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Minneapolis, MN. To find more information about Universal Hospital Services, Inc., please visit www.uhs.com
Assembly Biosciences (NASDAQ: ASMB) is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live microbial biotherapeutic candidates with Assembly`s fully integrated platform, including a robust process for strain identification and selection, GMP banking and production, and targeted delivery to the lower gastrointestinal tract with the GEMICEL® technology. We pride ourselves on creating a culture and work environment that is scientifically driven, ambitious, and collaborative. We encourage diversity of thought that leads to great innovation and are looking to add to our dynamic team great people who are driven to transform the lives of patients. We believe our Microbiome platform represents a best in class approach to developing biopharmaceutical agents from live biotherapeutic products. ABI-M201, our lead program in mildly to moderately active ulcerative colitis (UC), is currently in a phase 1b clinical trial. This program is part of a broader collaboration we established with Allergan in 2017 for gastrointestinal programs such as UC, Crohn`s disease and Irritable Bowel Syndromes with potential total development and commercial milestones of up to $2.8 billion. Our internal pipeline comprises first in class or best in class live microbial biotherapeutic approaches in areas such as oncology, immune mediated and metabolic disorders, and other areas of high medical need. Assembly is headquartered in Carmel, Indiana, while the R&D headquarters is in South San Francisco. The Company also has a microbiome manufacturing facility in Groton, CT, and offices in China.